Finance

Lists
Why is 069620 up 2,86%?
Dive Deeper
069620:KRX
Daewoong Pharma
108 000,00 KRW
+2,86%
(+3 000,00) 1D
19-окт., 13:08:31 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 069620...
Open
105 300 KRW
High
108 500 KRW
Low
104 000 KRW
Mkt. cap
1,25 трлн
Avg. vol.
19,18 миң
Volume
10,61 миң
Dividend
0,56%
Quarterly dividend
150 KRW
Ex-dividend date
2023-ж., 27-дек.
P/E ratio
6,36
52-wk high
199 400 KRW
52-wk low
101 900 KRW
EPS
16 988 KRW
Shares outstanding
11,59 млн
No. of employees
2 миң
Open
105 300 KRW
High
108 500 KRW
Low
104 000 KRW
Mkt. cap
1,25 трлн
Avg. vol.
19,18 миң
Volume
10,61 миң
Dividend
0,56%
Quarterly dividend
150 KRW
Ex-dividend date
2023-ж., 27-дек.
P/E ratio
6,36
52-wk high
199 400 KRW
52-wk low
101 900 KRW
EPS
16 988 KRW
Shares outstanding
11,59 млн
No. of employees
2 миң
News stories
From web sources and news partners
Profile
Daewoong Pharmaceutical Co., Ltd. is a pharmaceutical company headquartered in Seoul, South Korea. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products, including prescription and over-the-counter healthcare products. Wikipedia
About Daewoong Pharma
CEOChang-jae Lee | Seongsoo Park
Employees1,89 миң
Founded1945
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
411,83 млд
397,12 млд
377,80 млд
448,46 млд
Cost of goods sold
198,11 млд
185,96 млд
196,61 млд
199,39 млд
Cost of revenue
198,11 млд
185,96 млд
196,61 млд
199,39 млд
Research and development expenses
8,31 млд
139,98 млд
16,11 млд
14,81 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
144,21 млд
23,12 млд
136,65 млд
154,92 млд
Operating expense
156,83 млд
169,10 млд
158,98 млд
181,01 млд
Total operating expenses
354,94 млд
355,06 млд
355,59 млд
380,40 млд
Operating income
56,89 млд
42,06 млд
22,21 млд
68,07 млд
Other non operating income
-1,16 млд
2,77 млд
1,52 млд
-36,53 млд
EBT including unusual items
54,73 млд
68,97 млд
33,97 млд
21,89 млд
EBT excluding unusual items
54,73 млд
88,02 млд
11,82 млд
21,89 млд
Income tax expense
7,42 млд
-16,73 млд
8,46 млд
1,98 млд
Effective tax rate
13,56%
-24,26%
24,89%
9,02%
Other operating expenses
1,17 млд
1,17 млд
1,88 млд
1,61 млд
Net income
46,37 млд
89,84 млд
25,90 млд
33,37 млд
Net profit margin
11,26%
22,62%
6,86%
7,44%
Earnings per share
-
-
-
-
Interest and investment income
-
1,12 млд
1,74 млд
-
Interest expense
-
-3,53 млд
-8,00 млд
-
Net interest expenses
-
-2,41 млд
-6,26 млд
-
Depreciation and amortization charges
1,77 млд
1,43 млд
1,15 млд
7,94 млд
EBITDA
69,45 млд
56,04 млд
38,38 млд
92,95 млд
Gain or loss from assets sale
-12,80 млн
-52,31 млд
35,01 млн
-7,54 млн
AI content may include mistakes. Learn more
Google колдонмолору